Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|9149||ETCTN||Molecular Profiling-based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors||Adult CIRB - Late Phase Emphasis||Available to Open|
|8329||ETCTN||A Phase I/II Trial of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients with Solid Tumors (Phase I) and Relapsed Ovarian Cancer or Primary Peritoneal Cancer (Phase II) After Prior Platinum Containing First-Line Chemotherapy||Adult CIRB - Early Phase Emphasis||Available to Open|
|7977||ETCTN||A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) Plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients with Advanced Solid Tumors||Adult CIRB - Early Phase Emphasis||Available to Open|
|10388||ETCTN||A Phase I Trial of Triapine and Lutetium Lu 177 Dotatate in Combination for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)||Adult CIRB - Early Phase Emphasis||Available to Open|
|10349||ETCTN||A Phase 1 Trial of the p97 Inhibitor CB-5339 in Patients With Advanced Solid Tumors and Lymphomas||Adult CIRB - Early Phase Emphasis||Available to Open|
|10335||ETCTN||A Phase 1 Study of Lenalidomide in Combination with EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL)||Adult CIRB - Early Phase Emphasis||Available to Open|
|10330||ETCTN||A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma||Adult CIRB - Early Phase Emphasis||Available to Open|
|10329||ETCTN||Phase I Sequential Trial of Agents Against DNA Repair (STAR)||Adult CIRB - Early Phase Emphasis||Available to Open|
|10327||ETCTN||A Phase 1 Trial of MLN0128 (sapanisertib) and CB-839 HCl (telaglenastat) in Advanced NSCLC Patients||Adult CIRB - Early Phase Emphasis||Available to Open|
|10324||ETCTN||A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With M3814 in Platinum-Resistant or Ineligible Ovarian and Related Cancers with Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC)||Adult CIRB - Early Phase Emphasis||Available to Open|